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NONOPIOID THERAPIES IN THE TREATMENT OF CHRONIC PAIN AND 
THEIR ABILITIES TO REDUCE OPIOID PRESCRIPTIONS 
SHAUN C. ANTONIO 
ABSTRACT 
Introduction: 
 It is estimated that 100 million individuals suffer from chronic pain in the 
United States. Many of the options involved in chronic pain management have 
limited effectiveness come with risks of addiction, and/or have numerous side 
effects. The toll of chronic pain is even more substantial when complications with 
addiction arise. With an estimated 13.7% of adults having admitted to using pain 
relief medication for nonmedical purposes in the United States totaling a cost of 
approximately 55 billion dollars annually, the combined burden of chronic pain 
and addiction is considerable. To curb the sufferings created by chronic pain, it is 
essential to investigate its sources, the risks involved with current treatments, 
and alternative methods to alleviate chronic pain. 
 
Purpose: 
 The objective of this study is to review the current literature on the topic of 
nonopioid therapies in the treatment of chronic pain, their ability to reduce opioid 
prescriptions, and assess their pros and cons. Three different forms of alternative 
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treatments were chosen: 1) psychotherapeutic treatment Cognitive Behavioral 
Therapy, 2) Eastern Medicine Acupuncture, and 3) pharmacological class 
cannabinoids.  
 
Results and Conclusion: 
 The current literature on alterative therapies show that cannabinoids had 
the most potential to decrease pain, followed by CBT, and acupuncture showing 
the least consistent efficacy. The literature on CBT elucidate a great potential to 
decrease the use of prescribed opioids without increasing pain while 
cannabinoids showed a synergistic effect with opioids. The combined results for 
acupuncture were not consistent, with only one of the studies showing potential 
to reduce the use of opioids, while the others showed no difference between real 
and sham acupuncture.  
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INTRODUCTION 	  
 It is estimated that 100 million individuals suffer from chronic pain in the 
United States. Many of the options involved in chronic pain management have 
limited ineffectiveness, come with risks of addiction, and/or have numerous side 
effects (IOM, 2011). With a lack of physicians specializing in pain medicine, the 
responsibilities of caring for the millions of people suffering from chronic pain has 
fallen largely to the primary care physicians (Peppin, 2015). Over the past 
decades there has been an overreliance on the prescription of opioid-based 
drugs for the treatment of chronic pain. This can be seen in the increase of opioid 
prescriptions by 176% between the years of 1997 and 2006 (Turk, 2011). This is 
in part due to a lack of comfort that physicians feel in dealing with chronic pain 
management, misconceptions about the risks and benefits of opioids, and a lack 
of appreciation for alternative treatments. A scenario made all the more difficult 
by the high volume of patients. 
 Chronic pain is described as any pain lasting longer than 3-6 months, and 
can range from mild to totally debilitating. This is a broad set of symptoms that 
has numerous etiologies that include: neuropathy, fibromyalgia, cancer-related, 
spinal injury, migraines, arthritis, and many others. Adding to the wide range of 
origins, the complexity of chronic pain management is confounded by individuals' 
psychiatric and medical comorbidities, social aspects, and personal lifestyle 
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(Peppin, 2015). Some of the most important factors involved in a patient's 
successful outcomes from therapies were their body mass index, psychiatric 
diagnosis, surgical history, sleep disorder, history of traumatic brain injury, and 
single or multiple complaints of pain (Peppin, 2015). Many of these factors tend 
to create a feedback loop that increases the patient's pain while hindering their 
ability to cope. An example of this would be when a patient in pain is unable to 
get adequate sleep due to discomfort. This lack of sleep heightens their 
perception of pain, thus leading to greater frustration and pain levels.  
 The perception of pain has been a center of much research, unveiling a 
complicated system of positive and negative signaling in the central and 
peripheral nervous system. Additionally, these signals do not act in a vacuum, 
and are affected by a number of psychological and environmental factors. 
Evolutionarily, pain perception has been vital for survival to avoid noxious and 
dangerous stimuli so that an organism will avoid the unpleasant feelings and 
emotional experiences associated with the threat of or actual tissue damage 
(Tracey, 2012).     
 The mechanism of pain perception in a healthy individual begins with an 
outside stimulus that excites the peripheral nociceptors. These signals are 
carried into the central nervous system (CNS) through the dorsal root ganglion to 
the dorsal horn of the spinal cord by primary afferent neurons, either 
unmyelinated slow conducting C fibers or myelinated fast conducting A delta 
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fibers. In the spinal cord, the signals travel up the spinolthalamic tracts to the 
somatosensory cortex. The descending pain modulatory system (DPMS), 
composed of the periaqueductal gray and the rostral ventromedial medulla, is 
where the perception of pain is modulated, being inhibited or amplified. Once 
passing the brainstem and acted on by the DPMS, the signal continues to the 
higher centers of the brain such as the amygdala and hypothalamus. (Tracey, 
2012). Some of the neurotransmitters that amplify the sensation of pain 
throughout the path include glutamate and substance P. Those that are inhibitory 
include endogenous opioids and gamma amino butyric acid (GABA). Beyond the 
physiological response, an individual's emotional state and genetics can alter 
how pain is perceived (Tracey, 2012).      
 This interplay between physiology and behavior has led to the creation of 
different theories to explain how and why pain is perceived, and what changes 
occur when acute pain transitions into a state of chronic pain. In the Cartesian 
Model of pain by Rene Descartes, considered the classical nociceptive concept 
of pain, a painful stimulus causes a signal to be sent through the nerves, that he 
thought were hollow tubes, into the brain. There, information is encoded, and the 
body’s reactions are then sent out from the central nervous system back to the 
periphery. The Gate-Control Theory of Pain, postulated by Ronald Melzack and 
Patrick Wall in 1965, poses that non-painful stimuli closes gates along the pain 
perception path and inhibits the signal (Melzack, 2001). This theory opened 
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doors to new treatment modalities that focused on controlling the gateways to 
pain that are present in both the peripheral and central nervous system. 
However, these theories have not fully explained certain phenomenon, such as 
phantom limb pain, where a person missing a limb feels pain where there is no 
tissue. The Neuromatrix Theory of Pain expands on the Gate-Control Theory, 
delving deeper into the multidimensional relationship of the peripheral and CNS 
and their production of pain perception (Melzack, 2001). He states that the body-
self is a neuromatrix that creates a loop in which the spatial distribution and 
synaptic connections are set initially by the genetic determinants of the individual 
and then later sculpted by the inputs from the environment (Melzack, 2001). This 
remodeling of the neuromatrix allows for changes to occur, both in the peripheral 
tissue or the CNS, and allow for the development of phantom limb pain, as well 
as diseases such as neuropathy, fibromyalgia, and chronic pain.  
 Some of the changes that have been demonstrated in the transition of 
acute pain to chronic pain are the phenotypic switching, peripheral sensitization, 
central sensitization, and through epigenetic mechanisms. Phenotypic switching 
is caused by the nociceptors ability to conduct signals in both directions, both 
from the periphery to the CNS or from the CNS to the periphery. The later of 
these two does not occur under normal circumstances, but can change when 
damage to the tissue occurs causing an alteration to function in the cells called 
phenotypic switching (Blackman, 2014). These changes include an expansion in 
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the surface area that the nociceptors are sensitive to and an increased 
production of substance P by the Aβ fibers. All of this leads to a state of allodynia 
and hyperalgesia which during acute pain is an adaptive function to prevent re-
injury of the site that subsides once healed but remains in individuals with chronic 
pain  (Blackman, 2014). Peripheral sensitization is a change in the 
microenvironment in the peripheral tissue, usually caused by tissue damage and 
subsequent release if cytokines, chemokines, histamines, and other inflammatory 
mediators. These changes can disrupt the cellular integrity of the nociceptors and 
lower the threshold at the peripheral terminal leading to the hypersensitivity found 
in some patients with chronic pain (Blackman, 2014). In contrast, central 
sensitization is caused by the increased signal transduction of pain by the 
nociceptors in the CNS. This change can result in a similar fashion as peripheral 
sensitization through an alteration in membrane potential as well as a complex 
mixture in the reduction of inhibition, increased synaptic efficacy, and/or other 
structural alterations (Latremoliere, 2009). The sensitization of the cells maybe 
modulated or related to epigenetic changes in the cells. These are permanent 
changes to the chromatin structure of genetic material and alter the expression 
and functions of the neurons (Descalzi, 2015). With growing evidence that 
chronic pain is a disorder that originates from a diseased state of the 
somatosensory and pain signaling in the nervous system, new treatments that 
can effect different levels of pain signaling are being researched to be used alone 
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and in combination.  
 As the United States population has gotten older, chronic pain has 
become a larger burden. During the 1990's there was a push to treat those 
suffering more aggressively, and the prescription of opioids became the common 
practice for these patients. Opioids are a potent analgesic that interacts with 
three known G-coupled protein receptors; know as µ, δ, or κ opioid receptors. 
The most common opioid pharmaceutical drugs include: morphine, hydrocodone, 
codeine, methadone, fentanyl, tramadol, and buprenorphine. Each drug has its 
own unique potency, half-life, metabolism, and level of receptor activation 
(Bateman, 2012). Opioid receptors can be found both in the peripheral and 
central nervous system in nociceptors, spinal cord interneurons, brainstem, 
midbrain, and the cortex. When activated, the G-coupled protein receptors begin 
a cascade of events that lead to the hyperpolarization of the postsynaptic 
membrane due to the opening of the K+ and/or voltage-gated Ca++ channels 
(Stein, 2013). This causes a decrease in the propagation of signaling, and thus a 
reduction in pain perception.  
 While it is widely agreed on that the opioid class of drugs is a potent 
analgesic, that in subset of patients can be an effective treatment for chronic pain 
(Reube, 2015), their general safety and efficacy has come into question. As of 
February 2015, there were no studies on long-term opioid therapy that evaluated 
their effects on pain, function or quality of life at 1 year or longer, with most 
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placebo-controlled, randomized trials being between 6 and 12 weeks in length 
(Chou, 2015). This lack of information is disconcerting, especially when taking 
into account the amount of individuals taking these drugs for periods lasting 
multiple years. Furthermore, in those studies that lasted between 6 and 12 
weeks, their conclusions showed an equal or lesser efficacy of opioids in the 
treatment of pain compared to alternatives, such as non-steroidal anti-
inflammatory drugs and tricyclic antidepressants (Furlan, 2006). That although 
opioids outperformed placebo in the care of chronic pain, the use of other drugs 
had better results on patients’ functional outcome and were only outperformed by 
the strong opioids (oxycodone and morphine) in terms of pain relief (Furlan, 
2006).  
Despite the limited benefits of opioid therapies over the past couple of 
decades, opioid prescriptions have risen consistently. Correlating to this increase 
in prescription practices, emergency room visits due to opioid analgesic abuse 
has increased by 274%, from 1995 to 2005, and an increase in methadone 
related deaths by 390%, from 1999 to 2004 (Turk, 2011). Common signs and 
symptoms of an opioid overdose include: pinpoint pupils, respiratory depression, 
and loss of consciousness. A recent review of 38 studies found that opioid 
misuse and addiction rates are extraordinarily broad, ranging from <1% to 81%, 
with the majority of rates of misuse averaged between 21% and 29% (95% 
confidence interval (CI): 13%-38%) and rates of addiction between 8% and 12% 
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(95% CI: 3%-17%) (Vowles, 2015). This range is in part due to the poorly defined 
definition of the terms misuse and addiction. In addition to the threat of abuse 
and overdose, there are a number of side effects related to opioid use such as: 
constipation, urinary retention, nausea, dizziness, sedation, and tolerance. The 
body’s ability to build a tolerance to opioids is specifically problematic in the 
management of chronic pain. With ever-higher doses being needed to reach the 
same level of analgesia, there is an increasing risk for adverse effects and 
overdose. 
There are three features that characterize substance dependence: 
 
1) Strong desire to seek and take the drug 
2) An inability to limit intake 
3) Negative physical and emotional states when a substance is absent 
from the system   
(Koob, 2006) 
 
 These characteristics illustrate that dependence has both psychological 
and biological mechanisms of action. The neurobiological effect of opioids on the 
rewards pathway is thought to be a key aspect of the biology of addiction. β-
endorphins have not only been shown to have potent analgesic effects that are 
activated through opioids, but also induce a state of euphoria, and have an effect 
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on the rewards pathways and reinforce behavior (Roth-Deri, 2008). In the ventral 
midbrain, nucleus accumbens, and frontal cortex the opioids bind to the µ-opioid 
receptors where they act on the brains circuitry to elicit a pleasurable response 
that is similar to the natural rewards process. Not only does this activation of the 
rewards pathway reinforce the behaviors on the level of operant conditioning, but 
also causes physiological alterations to the mesolimbic dopamine system of the 
brain (Wise, 1996). Experiments have shown that during periods of withdrawal 
there are long lasting changes in neurochemical levels of dopaminergic and 
serotonergic transmission in the nucleus accumbens, which is thought to 
contribute to the negative motivational states during drug abstinence and 
increased urges to consume opioids (Koob, 2006).        
An added difficulty when treating chronic pain with opioids is the struggle 
involved in finding the differences between patients who are seeking drugs to 
ease their pain from those who are seeking them due to an addiction. These two 
behaviors are not mutually exclusive, and in many scenarios exist 
simultaneously. The drive for individuals to ease their suffering and the danger of 
addiction is a fine line that doctors continue to struggle with in the management 
of chronic pain. In part to avoid these dilemmas, the Centers for Disease Control 
came out with a set of 12 guidelines for prescribing opioids for chronic pain in 
March 2016. Its first recommendation revolved the initial avoidance of their 
prescription, stating that nonpharmacologic therapies, and more specifically 
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nonopioid pharmacologic therapies, are the preferred initial method of treatment 
for chronic pain. That physician should exhaust other methods to reduce patients’ 
pain and fully take into account both the benefits and dangers of opioids. Lastly, 
it is stated that if opioids were decided to be the best course of treatment, they 
should be used in combination with other therapies (Dowell, 2016).  
 
OBJECTIVES 
 
 The monetary cost of approximately 100 million individuals suffering from 
chronic pain is estimated to be $635 billion dollars annually (IOM, 2011). This 
cost is due to the burden on the healthcare system directly involved with the 
treatment of chronic pain as well as lost income. The toll of chronic pain is even 
more substantial when complications with addiction arise. With an estimated 
13.7% of adults having admitted to using pain relief medication for nonmedical 
purposes in the United States (Katzman, 2014), totaling a cost of approximately 
55 billion dollars annually (Fairbanks, 2014), the combined burden of chronic 
pain and addiction is considerable.  
 To curb the suffering created by chronic pain, it is essential to investigate 
its sources, the risks involved with current treatments, and alternative methods to 
alleviate chronic pain. The aim of this study is to review the current literature on 
this topic, and to assess the pros and cons of three different forms of alternative 
treatments for chronic pain: 1) psychotherapeutic treatment Cognitive Behavioral 
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Therapy (CBT), 2) Eastern Medicine Acupuncture, and 3) pharmacological class 
cannabinoids. The focus of this review will be to assess the efficacy of managing 
chronic pain with selected nonopioid treatments and its effect on reducing the 
use of opioid analgesics.  
 
COGNITIVE BEHAVIORAL THERAPY 
 CBT is a form of psychotherapy that focuses on changing behaviors and 
beliefs that are dysfunctional, and improve positive actions to achieve better 
outcomes. Its wide spread use in the treatment of patients with chronic pain 
began around 1960, and since then gained popularity with the emergence of 
Melzack and Wall’s gate-control theory of pain and Melzack's neuromatrix theory 
of pain (Roditi, 2011). These theories shifted the focus towards a combination of 
physical and pharmaceutical therapies to more effectively reduce the pain 
signaling from the nociceptors, as well as the psychological perception of pain.    
 With a growing body of evidence, the utilization of CBT therapy has 
become more common practice (Kerns, 2011). Despite this evidence, an agreed 
upon and coherent methodology about the content of the programs and an ideal 
length of treatment is still lacking. What has been largely agreed upon is that 
effective CBT consist of 3 major components: 
 
1) Creation of treatment rationale that helps individuals in pain to better 
	   	  12	  
understand that cognitions and behavior affect the pain experience and 
emphasizes the role that an individual can play in controlling their own 
pain.  
2) Cognitive and behavioral pain-coping strategies such as progressive 
muscle relaxation and cue-controlled brief relaxation exercises are used to 
decrease muscle tension, reduce emotional distress, and divert attention 
away from pain.  
3) Application and maintenance of learned coping skills.  
(Kerns, 2011) 
 
 Despite CBT's effectiveness, many people suffering with chronic pain 
have no or limited access to this treatment (Turk, 2002). Additionally, these 
communities have to overcome socio-economic, geographic, and weather-
related barriers to reach any of the available clinics. However, with advances in 
technology, namely the use of telehealth, those who are unable to travel are still 
able to reap the benefits of video sessions (Kerns, 2011). This caveat is unique 
to CBT and other psychological therapies.    
CBT Literature Review: 
"Group cognitive behavioral therapy to improve the quality of care to opioid-
treated patients with chronic noncancer pain: A practice improvement 
project" (Journal of the American Association of Nurse Practitioners, 2013, 
Vol.25(7), pp.368-376 26 NOV 2012) by Stacey K. Whitten, and Julie 
Stanik-Hutt 	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 Using an evidence-based quality improvement project, Whiten and Stanik-
Hut set out to enhance the treatment of patients with chronic noncancer pain 
(CNCP) that were being treated with opioids in conjunction with the use of CBT 
(Whiten, 2013). Based on their research, they created a 6-week long group CBT 
program, facilitated by a psychotherapist and primary care nurse practitioner. 
Treatment procedures were as follows: 
• 6 weekly classes for 2 hours: 15 min introduction, 30 min discussion of 
the homework assignment, 45 min presentation on a pain-related 
topics, 15 min of gentle stretching exercises, and educational session  
• Education included the science of chronic pain, relaxation techniques, 
automatic thoughts and cognitive restructuring, stress and anger 
management, pleasant activity scheduling, time-based pacing, sleep, 
relapse prevention, and flare-up planning 
• Each participant was called at home several days after every class to 
discuss class material and homework assignments 
 
  Outcomes were collected at the beginning of week 1 of treatment and 
again at the end of week 6. Data consisted of the Beck Depression Inventory II 
(BDI-II), the Short Form-36 (SF-36), the Brief Pain Inventory (BPI), and the 
Patient Global Impression of Change (PGIC) questionnaire.   
 Invitation to participate in the study was sent to 80 patients that were 
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eligible to partake in the program, of which only 28% (n=22) agreed and 
completed all 6 weeks. Reasons for non-completion included: travel difficulties, 
dislike of groups, other responsibilities, past completion of pain group, and 
inability to attend due to increased pain. The most common pain reported was 
neck and back pain (86.4%) and the average daily dose of morphine equivalent 
was 69mg.  
 
Results:  
 Through the course of group CBT treatment, patient surveys and scores 
showed improvements in all aspects. Slight and moderate gains were seen in 
their SF-36 physical scores, which rose from 28.8 to 31.968 (p=0.102), BPI 
scores decreasing from 5.6 to 4.9, and PGIC scores increasing from 3.77 to 5.09 
(p=0.02). Large improvements were seen in the SF-36 Mental reports that rose 
from 31.968 to 40.223 (p=0.001) and BDI-II scores lowering from 22.5 to 14.36 
(p<0.001). Although end dose of opioids were not measured in all of the patients, 
4 of the participant were tapered off of opioids under the supervision of their 
provider or discontinued use on their own.  
 
Discussion: 
 The results indicate that there is a possibility that chronic pain 
management can be enhanced through the use of CBT. Although there was not 
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statistical significance in the difference between the pre and post BPI Scores, 
their was a general trend of reduced pain, being rated at 5.6 pre-test and 4.9 
post-test. Furthermore, the data indicated that there was a correlation to CBT 
therapy and a patient's mental well-being and happiness that can vastly improve 
a patient's quality of life. The study mentioned that 4 patients ended opioid 
treatment, but no other medication measurements or patterns were discussed. 
The studies greatest shortcomings were the small population size, a lack of a 
control group, possibility for self-selection bias, and a lack of diversity in the 
sample.  
 
"Patients with problematic opioid use can be weaned from codeine without pain 
escalation" (Acta Anaesthesiologica Scandinavica, 2010, Vol.54(5), 
pp.571-579) by Nilsen, H. K., Stiles, T. C., Landrø, N. I. ; Fors, E. A., 
Kaasa, S., Borchgrevink, P. C. 
  
 This study looked to find if CBT could be used in patients with chronic pain 
and problematic opioid use to reduce their dose without a significant rise in pain 
or reduction in quality of life. 17 patients with CNCP for greater than 6 months, an 
average reported pain by the Numeric Rating Scale (NRS) for pain of 5 or 
greater, and at least 3 months use of short-acting codeine with a daily dose of at 
least 180 mg, problematic opioid use, and the patient having formally requested 
to increase codeine to the maximum recommended dose of 240 mg were invited 
to participate in this study. Of these 17 patients, 3 refused to reduce codeine and 
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3 had concurrent unacceptable levels of other drugs and were excluded from the 
trial, leaving 11 patients that participated in the study.     
  There were 4 sets of data collected during the course of treatment and at 
the 3 month follow up: codeine intake and withdrawal symptoms, pain 
measurements using BPI, SF-36, and a Neurocognitive tests (Stroop Color 
Naming Test). Measurements were collected at 3 intervals: pre-treatment, post-
treatment, and at 3 month follow-up. Additionally codeine dose and pain intensity 
were measured at the mid-point of treatment.     
 Treatment consisted of 6, 1 hour CBT sessions, over an 8 week period. At 
the beginning of the study, patients agreed to taper codeine dose to 50% at week 
4 and 0% by the end of week 8. This goal was reassessed at an individual level 
during week 4 of the study and individual goals were set based on the success of 
the prior 4 weeks. The first 1 hour session consisted of patient assessment and 
education on the importance of opioid reduction and cognitive-behavioral model 
of pain. The following sessions were centered on the identification, monitoring, 
and reality testing of negative automatic thoughts around pain and codeine, in 
accordance to the CBT theory. Homework assignments were given to monitor 
these automatic thoughts, and gradually challenge them using verbal 
reattribution techniques. The end goals of these CBT methods were to develop 
realistic and positive thoughts about their personal abilities to cope with pain and 
reduce opioid use.    
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Results: 
 All patients were able to significantly reduce opioid use through the 8 
week study period and at the 3 month follow-up. The mean values of codeine use 
prior to treatment, mid (4 weeks), post (8 weeks), and at follow up (3 months) 
was 237.3, 120.0, 45.0, and 47.7, respectively. Using a one-way repeated 
measures ANOVA, there was a significant effect for time [F(3, 8)=43.5, P<0.001]. 
Overall, there was an 80% reduction in codeine dose and 6 patients no longer 
taking opioids at the end of treatment. Of the 6 patients, 5 were still not taking 
codeine at the 3 month follow up appointment. 
 Through the 8 week study period and at the 3 month follow up, patient 
pain, physical function, general and mental health did not show a statistically 
significant change. Pain intensity at the pre, post, and follow-up was 6.2, 5.8, and 
5.4, respectively [F(3, 8)=1.0, P>0.05]. Physical function improved non-
significantly from 55.0, 57.6, and 65.0 [F(2, 9)=3.6, P=0.072]. General health was 
34.1, 40.6, and 48.2 [F(2, 9)=2.4, P=0.150], and mental was 54.6, 54.9, and 60.7 
[F(2, 20)=0.8, P>0.5]. 
 
Discussion: 
 These results show the possibility to taper patients with problematic opioid 
use without an increase in patient reported pain using CBT. With an overall 80% 
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reduction in total opioid use, and all 11 patients significantly reducing their daily 
intake, and on average no increase in pain with a general pattern of reduction. 
The viability of CBT shows great potential to aid in reducing opioid prescriptions 
without increased pain. Shortcomings of this study include a small sample size, a 
lack of control group, inclusion of patients was based on willingness to decrease 
medication, and a short follow-up time.  
 
CBT Literature Summary and Additional Findings: 
 The literature on the reduction of opioids in the treatment of chronic pain 
shows that CBT is a viable option. In the first study reviewed, Whiten and Stanik-
Hut attempted to use group CBT to improve pain management. While there was 
not a statistical significance, there was a trend that alluded to the possibility that 
pain had been reduced through the CBT treatments. In the Nilsen et al. study on 
CBT treatment, the major outcome measured was a reduction in the reliance on 
opioid medication (Nilsen, 2010). At the conclusion of the 8 weeks of treatment, 
there was a drastic reduction in opioid use at roughly 80%. In addition to the 
drastic reduction in opioid use, most patients saw no increase in pain or a slight 
decrease. No adverse events were documented in the reviewed CBT studies. 
Overall, these results need to be taken as preliminary and with caution, both 
studies were conducted with small and limited sample sizes and lacked controls. 
Results from the literature found on CBT are summarized in Table 1.  
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  Additionally, these studies illuminated a number of benefits for individuals 
with chronic pain through CBT, especially in the realms of mental wellbeing. 
Whiten and Stanik-Hut's study measured the patients' mental health, depression, 
and global impression of change in addition to physical and pain scores. Both 
mental health and depression improved drastically, where as their global 
impression of change improved moderately. In the Nilsen et al. study on CBT 
treatment, the results were not as stark. There were 3 patients that had 
significant improvements in all categories and 2 who had a significant decline. 
This could imply that CBT may be more beneficial for sub-populations. It is also 
important to keep in mind that despite a drastic reduction in pain medication use 
during the study, overall health measures did not decline, possibly attributable to 
CBT. Neurocognitive functioning was also measured throughout this study, 
however the authors attribute the statistical significant gains made in these 
categories to the reduction in opioid medication and believed them to be 
unrelated to CBT. 
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Table 1. CBT Literature Review Summary 
Study Study type Groups n= 
Significant 
Results 
Summary 
Did the 
study 
decrease 
opioid use 
and/or pain 
Stacey K. 
Whitten 
2012 
Pre-post 
comparative 
design 
22 
SF-36 
Mental 
reports rose 
from 31.968 
to 40.223 
(p=0.001)  
 
BDI-II 
scores 
lowered 
from 22.5 to 
14.36 
(p<0.001) 
No 
significant 
reduction in 
pain  
 
4 patients 
weaned off 
opioids  
Nilsen, H. K. 
2010 
Pre–post 
design with 
follow-up 
(case series) 
no control 
group 
11 
80% 
reduction in 
codeine 
dose  
 
6 patients no 
longer taking 
opioids at 
the end of 
treatment, 5 
at the three-
month follow 
up  
Significant 
reduction in 
opioid use 
 
No 
significant 
change to 
pain 
 
ACUPUNCTURE 
 Acupuncture has been a component of Chinese medicine for over 2,500 
years, with the most common form using small needles inserted into the skin to 
stimulate energy flow. This form of therapy has its roots imbedded with 
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naturalistic theories such as Confucianism and Taoism, and use the frameworks 
of yin-yang, qi, and the five elements: earth, water, fire, metal, and wood, to 
conceptualize human health (Kaptchuk, 2002). Yin-yang is the idea that there are 
two opposing fields that exist in unison, and when applied to the human body, 
align organs into being in the field of either yin or yang. Qi, also known as Chi, is 
an energy that flows along channels called meridians, and must be maintained in 
order for an individual to be healthy (Weintraub, 2008). Along the principal and 
two other minor meridians lay 361 acupuncture points that can be points of 
treatment.  
 Acupuncture has largely moved away from mysticism and into the realm of 
science. Although initially skeptical of its legitimacy, many physicians have begun 
to use acupuncture to treat a number of ailments. A number of studies have 
shown evidence that it has efficacy in treating lower back pain, fibromyalgia, 
nausea, headache, and osteoarthritis (Weintraub, 2008). This relief in pain is 
thought to be in part due to the activation of small myelinated nerve fibers in the 
skin to send signals through the CNS and ultimately inhibit incoming pain signals 
and release endogenous opioids (Weintraub, 2008). The role of endogenous 
opioid release in acupuncture's analgesic effects has been supported through the 
use of naloxone to block its efficacy. Despite its growing use, there have been 
many inconstancies and some contradiction between studies. These 
discrepancies could be in part due to the inability to have double blind studies, 
	   	  22	  
difficulties with blinding and the creation of inert placebos, and individualized 
nature of treatment (Weintraub, 2008). 
 With the growing acceptance of acupuncture as a viable therapy, in 1976 
California became the first state to license acupuncturists. Since then, 
acupuncture has become the most widely used complimentary and alternative 
therapy, with several million treatments annually in the United States (Weintraub, 
2008).  
 
Acupuncture Literature Review: 
 
"The effect of electroacupuncture on opioid-like medication consumption by 
chronic pain patients: A pilot randomized controlled clinical trial" 
(European Journal Of Pain, 2008 Jul, Vol.12(5), pp.671-676) by Zhen 
Zheng, Runxiang J. Guo, Robert D. Helme, Andrew Muir, Cliff Da Costa, 
Charlie C.L. Xue 
 
 The study by Zheng et al. was a 20 week pilot, randomized, single blind 
trial comparing the efficacy of real electroacupuncture (REA) to reduce opioid-like 
medicines (OLM) and side effects in patients with CNCP compared to sham 
electroacupuncture (SEA). For the design of the acupuncture treatment, the 
Standard Recommendation in Clinical Trial for Acupuncture (STRICTA) was 
followed. Patients were chosen on the bases of reported CNCP for more than 3 
months and use of OLM, and the total sample size ended up being 35 (17 REA: 
18 SEA). Measurements for outcomes consisted of: OLM dose (converted into 
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morphine equivalents), side effects, pain intensity (use of visual analogue scales 
(VAS)), McGill Pain Questionnaire (MPQ), SF-36 surveys, and BDI. Data was 
collected using a subject diary during weeks 1 through 2 for baseline 
measurements, and then at treatment periods during week 3 through 8. During 
the follow-up weeks 9,12,16, and 20 a daily diary was kept.    
 Treatment in the REA group consisted of 2 pairs of acupuncture points, 
Shousanli LI10/Hegu LI4 and Zusanli ST36/Fenglong ST40, at an alternating 
frequency of 2 and 100 Hz. Additionally, upward of 5 supplementary sites were 
used depending on personal OLM side effects during treatment. The SEA group 
used acupuncture needles that were placed in non-stimulating and non-classical 
points connected to a mock electroacupuncture stimulator. Both groups received 
treatment twice a week, starting in week 3 through 8, lasting 30 minutes with 20 
minutes of electroacupuncture stimulation.    
 
Results: 
 Both the REA and SEA saw a statistically significant decrease in 
consumption of OLM, with a 39% for REA decrease and a 25% for SEA and a p-
value p < 0.001. The OLM difference between the 2 groups was not statistically 
different, as well as no differences in pain intensity, depression, and QoL. Of 
note, those who finished the 6 weeks of treatment in its entirety saw a reduction 
in OLM of 64% and 46% in the REA and SEA groups respectively. 
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 In the proceeding weeks, OLM increased gradually and was statistically 
significant by the 20th week compared to at the end of treatment.   
 
Discussion: 
 Both the sham and the real electroacupuncture groups showed an 
improvement in OLM usage and pain. Although real electroacupuncture was 
lower, it was not statistically different from the sham treatment. Blinding seemed 
to be effective, and there were no reports of patients knowing which group they 
were placed in. With both sham and real treatments having a significant ability in 
reducing OLM use and pain, there is a question over placebo effect or 
unintended effects of the SEA, and if so what that means for the efficacy of 
electroacupuncture. With such a small sample size, these issues cannot be 
resolved, but these results show that REA offers at least a plausible tool to 
reduce opioid use and chronic pain.    
 
"Analgesic Effect of Electroacupuncture in Postthoracotomy Pain: A Prospective 
Randomized Trial" (The Annals of Thoracic Surgery, 2006, Vol.81(6), 
pp.2031-2036) by Wong, Randolph H.L.; Lee, Tak Wai ; Sihoe, Alan D.L.; 
Wan, Innes Y.P.; Ng, Calvin S.H.; Chan, Simon K.C.; Wong, William W.L.; 
Liang, Yuet Mei; Yim, Anthony P.C. 
  
 This study was a randomized, double-blind, placebo controlled experiment 
that compared REA to SEA for postthoactomy pain. Eligible participants were 
patients with operable non-small cell lung carcinomas, with tumor size equal or 
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larger than 4cm in diameters. 32 patients were referred; with 5 patients declining 
to participate, the sample size was 27. All patients had anatomic lung resection 
through a thoracotomy, and received the standard dose of 0.1mg/kg morphine 
and 2mg/kg fentanyl anesthetic and a maintenance dose of 0.05mg·kg−1·h−1 of 
morphine. Patients and postoperative health care members were blinded to 
which treatment was being given.   
 Treatment with 2, 30 min acupuncture sessions began as soon as the 
patients returned from surgery, and continued for 7 days for all participants. 
Treatment was performed by an accredited physiotherapist, with a diploma in 
acupuncture from Hong Kong Baptist University and the International 
Acupuncture Institute. Additional treatment for all participants included IV patient-
controlled analgesia (PCA) with 1mg of morphine per bolus with a lockout time of 
5 minutes during the first 3 days post-surgery, a prescription of 640mg 
acetaminophen and 65mg dextropropoxyphene 4 times per day while in the 
hospital. Acupuncture points that were selected included the LI 4, GB 34, GB 36, 
and TE 8 points ipsilateral to the side of the thoracotomy due to their influence on 
the chest wall and upper body. Electrostimulation was adjusted until a state of 
De-Qi was reached, which is characterized by a sensation of heaviness, fullness, 
and numbness. SEA used the same points, however blunt-tip needles were used 
as well as pseudostimulation where no electrical current was used and De-Qi not 
reached.   
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 Measurements consisted of: VAS pain score (0mm-100mm), PCA 
morphine usage, peak flow rate, chest drain duration, and postoperative 
complications. These measurements were collected at 1 hour intervals 
postoperatively, on days 1 through 3 collections were at 8am, 2pm, and 8pm, 
and from days 4 through 7 at 8am.  
 
Results: 
 The day of surgery and the first postoperative day resulted in no statistical 
difference between REA and SEA, however on the second postoperative day 
there was a statistical difference of 7.5mg for the REA group and 15.7mg in the 
SEA group with a p-value of 0.035. Although the VAS scored showed slightly 
lower pain reporting by patients in the REA group, there was no statistical 
significance.  
 
Discussion: 
 Initial PCA use post surgery does not seem to have been affected by REA 
treatment, but second day usage decreased significantly compared to SEA. 
Showing a potential in REA to reduce the need for opioid use postoperatively at 
different times. Although pain measurements were general lower in the REA 
group, all but day 5 were statistically insignificant. Similar to the last acupuncture 
study, the sample size was small, and the possibility of REA remains as a 
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solution in aiding the relief of pain and reducing opioid use. 
 
"Randomized controlled trial of a special acupuncture technique for pain after 
thoracotomy" (The Journal of Thoracic and Cardiovascular Surgery, 2008, 
Vol.136(6), pp.1464-1469) by Deng, Gary; Rusch, Valerie; Vickers, 
Andrew; Malhotra, Vivek; Ginex, Pamela; Downey, Robert; Bains, Manjit; 
Park, Bernard; Rizk, Nabil; Flores, Raja; Yeung, Simon; Cassiletha, Barrie 
 
 The study conducted by Deng et al. was a randomized control design, 
comparing intradermal acupuncture needles to sham techniques in the treatment 
of acute and chronic postthoracotomy pain. Using indwelling needles over a 
longer period was thought to be more appropriate in Western culture by reducing 
the need for repeated appointments to receive treatment. All subjects were 
patients with cancer and scheduled for a unilateral thoracotomy at the Memorial 
Sloan–Kettering Cancer Center. Patients were blinded during the course of the 
study. Acupuncturists and the designated research assistant were not blinded to 
treatment groups.  
 Treatment began between 2 hours of surgery and after an epidural 
catheter had been placed, but prior to anesthetization. There were 9 sites on 
each side of the spine chosen for needle placement (1.5mm long and 0.2mm 
diameter) on the BL-12 to BL-19 acupuncture points with the addition of a stud 
on each leg at the ST-36 point and 1 in each auricle on Shenmen point. The BL 
points have been shown to have antinociceptive effects prior to surgery where as 
the ST and Shenmen points are commonly used in the treatment of pain in 
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acupuncture therapies. The acupuncture group had short needles that went into 
the epidermis with a ring on the end (4mm diameter) to prevent the needle from 
going too deep. The studs were covered with tegaderm transparent films, and 
replaced after 1 week from initial treatment, the ST-36 studs removed 1 week 
later, and 3 weeks later the back studs were removed. The total treatment time 
was 4 weeks. The control group followed the same protocols, with the exception 
of using studs with no needles for treatment, studs were placed between the 
upper and lower border of the spinous processes T2-T10 about 1.25cm from the 
spine, leg studs were about 5cm posterior of the GB-34, no use of ear studs, and 
were placed on the anterior of the arm roughly 5cm of the midpoint of the 
antecubital crease. These positions were chosen based on their lack of known 
acupuncture effects and to avoid a stimulation of the acupuncture points meant 
to be stimulated in the treatment group.         
 Measurements taken were the BPI at baseline, 10, 30, 60, and 90 days 
postoperative, and total opioid use and Medication Quantification Scale (MQS) at 
the end of weeks 1, 2, and 4 postthoracotomy. 
 
Results: 
 While results slightly favored acupuncture over the placebo in the 
treatment of acute and chronic postthoracotomy acute and chronic pain, the 
differences were not statistically significant. The morphine equivalents for the 
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acupuncture favored the sham slightly with 1530mg compared to 1563mg for the 
real electroacupuncture treatments, with a p-value of 0.6. The total pain 
measurements favored acupuncture over sham on days 10 by 0.21 (p=0.6), 30 
by 0.13 (p=0.7), and 60 by 0.48 (p=0.2), however this was not statistically 
significant. It was concluded that REA was not a viable option to be used for pain 
management in patients who had under gone postthoracotomy surgeries.       
 
Discussion: 
 Compared to the last 2 studies on management of postthoactomy pain 
with the use of acupuncture therapy, Deng et al. had a large sample size and 
lengthened the study's observational time. Through the course of treatment the 
benefits of REA over SEA were not noted to any statistical significance, and at 
times showed SEA out-performing REA. In contrast to the past 2 studies, these 
results do not indicate that the use of REA was effective in the management of 
acute or chronic postthoactomy pain nor in the treatments ability to reduce the 
use of opioids. 
 
Acupuncture Summary and Additional Findings: 
 In the reduction of opioids in the treatment of chronic pain, acupuncture 
seems to be a questionably effective form of treatment to reduce opioid 
prescriptions in patients with chronic pain. In the acupuncture studies, the sham 
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placebo treatment groups showed roughly the same efficacy as the real 
electroacupuncture groups. In the 20 week pilot study by Zheng et al., there was 
a significant reduction in pain postoperatively, however the REA group fair only 
slightly better to the SEA group (Zheng, 2008). The reduction in pain may have 
been caused by placebo or added benefits to both groups through the pressure 
stimulation in the SEA group. The acupuncture study by Randolph focused 
mostly on the short-term reduction in pain and opioid use (Randolph, 2006). 
Similar to the other studies, no statistically significant difference was seen 
between the SEA and REA groups to reduce patient pain perception. The most 
promising results were on the second day post-operatively, when there was a 
significant reduction in PCA use in the REA group compared to SEA. The results 
in the study by Deng and colleagues' were the least in favor of acupuncture 
(Deng, 2008). This study concluded that REA had no clinical significance in 
short-term post operative or chronic pain outcome, and did not recommend its 
use. Overall, the results of REA were very limited, and not consistent between all 
of the studies. Results are summarized in Table 2.           
 In the use of REA treatment, very few adverse events were noted, none 
being substantial, and most being unrelated to the treatment directly. The only 
adverse events found were during the study conducted by Zheng, in which there 
were 52 adverse events (19 SEA and 33 REA) during the 345 treatment sessions 
(Zheng, 2008). 2 participants withdrew from the study stating that it was due to 
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mildly adverse effects, and no serious events were reported. Based on the 
collected data in these studies, electroacupuncture is a safe treatment method 
option with little risks, however possibly lacks in efficacy.  
 Acupuncture through the ages has been used for a number of different 
ailments other than pain. In the study conducted by Zheng and his colleagues, 
both REA and SEA showed a significant reduction in opioid induced side affects, 
40% and 45% respectively (Zheng, 2008). These side affects included: fatigue, 
drowsiness, lethargy, constipation, nausea, dizziness, blurred vision, sedation, 
and anxiety. Similar to the differences in pain reduction, these results were not 
statistically different from each other but may have been induced from pressure 
stimulation in the SEA group. Additionally, no difference was detected in 
depression or quality of life measurements. The results from Wong et al. did not 
include any quality of life measures or depression scales, but did find a 
statistically insignificant reduction in antiemetic use in the REA at group 
compared to the SEA group (p=0.6). 
 Of special note, for acupuncture there are some concerns about the use of 
sham acupuncture as an effective placebo. It has been postulated that there are 
benefits caused by the sham therapies, thus skewing the data towards the null 
(Weintraub, 2008). Refinement of sham techniques and better techniques to 
measure controls need to be researched to gain a better understanding of 
acupuncture's potential as a therapy before fully disregarding its potential 
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Table 2. Acupuncture Literature Review Summary 
Study Study type Groups n= 
Significant Results 
Summary 
Did the study 
decrease opioid use 
and/or pain 
Zheng, Z. 
2008 
Randomized, 
single blind 
trail 
35 
 39% reduction of 
opioid use in REA 
group and decrease 
of 25% for the SEA 
group (p < 0.001)  
No significance 
between treatment 
groups 
Wong, 
Randolph 
H.L. 2006 
Randomized, 
double-blind, 
placebo-
controlled 
trial 
27 
On second day of 
postoperative care, 
REA use of PCA 
was 7.5mg 
compared to 15.7mg 
for SEA (p=0.035) 
Reduction of PCA 
on second 
postoperative day in 
REA group 
 
No significant 
difference in Pain 
Deng, 
Gary. 
2008 
Randomized, 
sham-
controlled, 
subject-
blinded trial 
162 
No statistically 
significance between 
REA and SEA found 
No reduction in 
opioid use or pain 
between REA and 
SEA found 
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CANNABINOIDS 
 Cannabis is a flowering plant that is indigenous to parts of Asia. Its 
medicinal uses have been seen in ancient Egypt and China roughly 5,000 years 
ago, and along with opioids, it is one of the oldest known substances still used 
medicinally. In 1941 the U.S. Pharmacopoeia stated cannabis had uses in 
treating fatigue, coughing, rheumatism, asthma, delirium tremens, migraine 
headaches, and the cramps and depressions associated with menstruation 
(Lucas, 2012). In 1970, the Controlled Substance Act was passed making 
cannabis based products a Schedule I drug, deeming it a dangerous substance 
with no accepted medical use. Through the 80's and majority of the 90's it 
remained an integral part of the War on Drugs, but has since become more 
widely accepted. It is now the third most used recreational drug in the United 
States behind alcohol and tobacco (Reisfield, 2009). Laws and their enforcement 
have become more lax, with 23 states having legalized cannabis for the use in 
adults for chronic pain management and other medicinal uses to varying 
degrees. Some of the possible uses seen in studies showing dose-dependent 
pharmacologic actions include: analgesia, muscle relaxation, anti-inflammatory 
effects, neuroprotection in ischemia and hypoxia, enhanced wellbeing, and 
anxiolysis (Carter, 2011). An additional trend in states that had legalized the use 
of medical marijuana between the years of 1999 and 2010 was a systematic 
decrease in opioid related deaths. In these 10 states there was a 24.8% lower 
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mean annual opioid overdose mortality rate (95% confidence interval= -37.5 to -
9.5; p=0.003), with a trend that strengthened over time (Bagcchi, 2014).  
 The major psychoactive compound in cannabis is Δ-9-
tetrahydrocannabinol (THC), a lipophilic, 21-carbon terpene, however there are 
more than 85 known cannabinoids found in the plant that grow in different ratios 
depending on the plants strain and environment (Lucas, 2012). These drugs 
react with the 2 known classes of cannabinoid receptors: Subtype 1 (CB1) and 
subtype 2 (CB2) expressed mostly in the brain and the periphery, respectively. 
Through these receptors cannabinoids give analgesic effects by acting on the 
brain, spinal cord, and periphery through neurons in the rostroventral medulla 
and periaqueductal grey, inhibition of GABA, glycine, and glutamate release, and 
through effects on inflammation and cytokine production (Carter, 2011). The 
endogenous forms of cannabinoids that react with the CB1 and CB2 receptors 
are called endocannabinoids. Unlike opioid receptors, CB1 and CB2 are largely 
absent from the brain stem and thus do not share the respiratory depressive 
effects that opioids have. This physiological difference between opioids and 
cannabis is why there are no records of individuals dying from a cannabis 
overdose and that the substance has no known lethal dose (Carter, 2011).  
 
Cannabinoids Literature Review: 	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"Cannabinoid–Opioid Interaction in Chronic Pain" (Clinical Pharmacology & 
Therapeutics. Volume 90, Issue 6, pages 844–851, December 2011) by 
D.I. Abrams; P Couey; S B Shade; M E Kelly; and N.L. Benowitz 
  
 The purpose of this study was to examine the affects that vaporized 
cannabis would have on the kinetics of sustained-release morphine and 
oxycodone, and the rating of pain in chronic pain patients. 21 patients were in the 
study, with chronic pain from musculoskeletal (7), posttraumatic (4), arthritic (2), 
peripheral neuropathy (2), cancer, fibromyalgia, migraine, multiple sclerosis, 
sickle cell disease, and thoracic outlet syndrome (1 each). Of these patients, 10 
were on morphine (mean dose of 62mg twice a day) and 11 were on oxycodone 
(mean dose of 53mg twice a day). Patients were admitted into a 5 day inpatient 
setting, where they inhaled vaporized cannabis once on the first evening, 3 times 
a day on days 2 through 4, and in the morning on day 5. Blood samples were 
collected in 12 hour intervals ever 1, 2, 4, 6, 8, 10, and 12 hour on days 1 
through 5 to determine drug pharmacokinetic effects, and pain was assessed 
daily. Pain, stimulation, anxiety, sedation, feeling down, hunger, mellowness, 
confusion, irritation, depression, feeling withdrawn, dizziness, nausea, and 
dryness of the mouth were measured using the standard VAS ranging form 0 (no 
effect) to 100 (max effect). These were measured through Drug Effects 
Questionnaires that were taken by the patient before the morning opioid dose 
and then 30 min, 1, 2, 4, 6, 8, 10, and 12 hours afterwards through the 5 days.    
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Results:  
 
 After 5 days of treatment there was a significant overall decrease in 
reported pain perception from 39.6 (95% CI= 35.8, 43.3) to 29.1 (95% CI 25.4, 
32.8) overall. This decrease in pain was statistically significant for the total and 
for the morphine groups, but not the oxycodone group. There was an additionally 
significant decrease to the maximum concentration (Cmax) of morphine while 
patients were on cannabinoid treatment. The plasma concentration-time curves 
showed that there was no statistically significant change in the area under the 
curve.  
 
Discussion: 
 Patients who were treated with vaporized cannabis reported a significant 
decrease in pain perception, and additionally the Cmax of morphine was 
significantly decreased. These results indicate that the treatment of at least some 
opioids can be augmented with the treatment of cannabinoids through altering 
their pharmacodynamics. Limitations to this study include a small sample size 
and a lack of a control group. 
 
"Multicenter, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group 
Study of the Efficacy, Safety, and Tolerability of THC:CBD Extract and 
THC Extract in Patients with Intractable Cancer-Related Pain" (Journal of 
Pain and Symptom Management. Volume 39, Issue 2, February 2010, 
Pages 167–179) by Jeremy R. Johnson; Mary Burnell-Nugent; Dominique 
Lossignol; Elena Doina Ganae-Motan; Richard Potts; Marie T. Fallon  
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 The 2 week study was a multicenter, double-blind, randomized, placebo-
controlled, parallel-group study in the evaluation of THC:Cannabidiol (CBD) in 
combination and THC extract alone on moderate to severe cancer-related pain 
management. Participants were selected on their use of strong opioids for 1 
week or greater to manage their pain associated with incurable malignancy. 
During the 2 day baseline period, patients kept diaries to record pain scores, 
background medications, and all additional breakthrough analgesia. On each of 
these 2 days, patients rated their pain severity at 4 or higher on the NRS. After 
the 2 day baseline period, patients were separated into 3 groups at random: 
THC:CBD extract, THC extract, or placebo. Patients kept records of the data 
throughout the study period in their diaries. Other data collected in the diaries 
included: sleep quality, nausea, memory, concentration, and appetite over the 
previous 24 hours using diary NRSs, and adverse events were reported during 
study visits. 
  Medication was delivered through a pump action oromucosal spray, 
delivering 100µL/pump. The THC:CBD device contained 2.7mg of TCH and 2.5 
CBD per 100µL, the THC device 2.7mg THC per 100µL, and the placebo device 
delivered excipients plus colorants. Patients were allowed a maximum of 8 
actuations every 3 hours and 48 actuations in any 24 hour period. Self-titration 
was used for each patient to reach their optimal dose over 7 days, allowing for a 
maximum increase number of sprays by 50% per day until treatments provided 
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sufficient relief and few side affects. Dosage of treatment was maintained at 
patient titrated levels for the remainder of the study.      
 
Results:  
 During the study period all groups reported a decrease in pain severity, 
with an adjusted mean reduction in NRS for THC:CBD by -1.37, THC by -1.01, 
and placebo by -0.69 with a statistically significance between the THC:CBD 
group and placebo having a p-value of 0.014. From baseline to the end of the 
trial there was no significant change in median oral morphine use in the 124 
patients for whom data was available. However, the THC:CBD group had a 
greater proportion of patients that reduced breakthrough doses (8 patients) 
compared to placebo (zero patients). There was a clinically significant reduction 
(at least 30% from baseline NRS) shown in 43% of those in THC:CBD group, 
23% in THC, and 21% in the placebo. 
 
Discussion: 
 The treatment combination of THC:CBD had a significant reduction in pain 
perception compared to placebo, and THC alone had a slight non-statistically 
significant difference. Although neither treatment had a significant difference in 
the amount of daily opioid dose, there was a significant reduction in breakthrough 
medication use in the THC:CBD group. The THC:CBD group also had twice as 
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many individuals reach a clinically relevant reduction of pain (30% or greater 
reduction in pain is considered clinically relevant). A number of treatment related 
adverse events and secondary outcomes were measured, the most significant 
result was an improvement in the BPI-SF-36 total score in the THC group. These 
results show the plausibility of decreasing severe cancer-related pain, and 
possibly another way to reduce opioids, especially pertaining to breakthrough 
medication. The largest limitation of this study was its reliance on patient 
surveys, many of which overlapped in question relevance.  
 
Cannabinoid Summary and Additional Findings:   
 Overall the cannabinoids showed an ability to reduce pain and some 
possibility to decrease opioid prescriptions. In the study conducted by Abrams 
and colleagues, there was a statistical significant reduction in pain perception in 
patients that used vaporized cannabis treatment concurrently with morphine 
(Abrams, 2011). This difference in pain perception between the morphine group 
and oxycodone group suggest that there may be clinically significant differences 
between the interactions of cannabis and different classes of opioid drugs. 
Additionally there was a significant reduction in the Cmax of morphine during the 
cannabis treatments. Although much of this is thought to be due to the slowed 
absorption rate caused by cannabis, there was a stark contrast compared to the 
oxycodone treatment group. They concluded that their findings suggest there is a 
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pharmacodynamics mechanism in which cannabis and opioids act with 
synergism (Abrams, 2011). In the study conducted by Johnson et al. there was 
also a statistically significant reduction in pain noted between the THC:CBD oral 
mucosal spray group compared to placebo, and although THC alone was lower it 
was not statistically significant (Johnson, 2010). Unlike the other studies, the data 
in reduction of opioids was not as strong, with no statistically significant reduction 
in opioid use in the 124 patients over the 2 weeks. The only significant change in 
opioid use was in the THC:CBD groups reduction in breakthrough medication. 
Results are summarized in Table 3.  
 Treatments with pharmacological agents usually come with higher 
inherent risks due to chemical interactions within the body. Cannabinoids are no 
exception to this pattern, as is shown by the greater adverse events in the 
literature compared to that of CBT and acupuncture therapies. In Abrams and his 
colleagues’ study, the results show a significant increase in a sensation of feeling 
high and stimulation, as well as a decreased sensation of hunger in the morphine 
groups. In the oxycodone groups, there was a significant increase in the 
sensation of feeling high and anxiety. Increased adverse effects were also 
demonstrated in the study conducted by Johnson et al. Of the 177 patients in the 
study, 106 (60%) reported adverse events related to the treatment that included: 
somnolence, dizziness, and nausea. Severities of these events were mostly in 
the mild to moderate range and were similar to past THC:CBD studies. Although 
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there were other incidences that occurred during this study, they were not 
attributed to the treatment.  
 In the cannabinoid studies there were slight non-statistically significant 
improvements seen in changes in appetite, anxiety, sedation, sleep quality, 
global health, emotional functioning, social functioning, insomnia, diarrhea, 
constipation, and even financial difficulties. The single significant result was the 
decrease in hunger in the study conducted by Abrams et al. from a score of 64.8 
to 29.44 (p=.04). This was however in contrast to the small increase in appetite 
measured at an increase of 0.24 (p=0.016) and a decrease in appetite loss of -
3.69 (p=0.875) in the THC:CBD group (Johnson, 2010). Many of these 
differences can be either benefits or drawbacks of cannabis treatments 
depending on the patient's specific needs and situations.  
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Table 3. Cannabinoids Literature Review Summary 
Study Study type Groups n= 
Significant 
Results 
summary 
Did the study 
decrease 
opioid use 
and/or pain 
D I Abrams. 
2011 
Dose-response 
comparative 
design study, 
non-blind, 
nonrandomized 
21 
Pain rating 
using the VAS 
significantly 
decreased 
from 39.6 to 
29.1 overall 
 
Significant 
reduction in 
Cmax of 
morphine 
group  
No reduction 
in opioid use 
 
Reduction in 
pain 
Jeremy R. 
Johnson. 
2009 
Multicenter, 
Double-Blind, 
Randomized, 
Placebo-
Controlled, 
Parallel-Group 
Study 
177 
Significant 
difference in 
reduction of 
pain between 
THC:CBD 
compared to 
placebo 
p=0.014 
 
Reduction of 
breakthrough 
medication 
use in 
THC:CBD 
group 
compared to 
placebo 
Reductions in 
pain and 
breakthrough 
medication 
use THC:CBD 
group 
compared to 
placebo 
 
 
CONCLUSION AND DISCUSSION 
 With so many individuals suffering from chronic pain in the United States, 
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finding a comprehensive, safe, and effective treatment modality is imperative. 
Although opioids offer some relief, especially in the short-term, they create a 
burden of misuse and untoward side effects. The current literature on the 
alternative therapies CBT, acupuncture, and cannabinoids show great potential 
to aid in the management of chronic pain while reducing the use of prescription 
opioids. Overall, cannabinoids had the most potential to decrease pain, followed 
by CBT, and acupuncture showing the least consistent efficacy. The literature on 
CBT elucidate a great potential to decrease the use of prescribed opioids without 
increasing pain and cannabinoids showed a synergistic effect in combination with 
opioids. The combined results for acupuncture were not consistent, with only one 
of the studies showing a significant potential to reduce the use of opioids, while 
the others showed no difference between real and sham acupuncture. Adverse 
events and side effects were greatest with cannabinoids, and included: feeling 
high, decreased sensation of hunger, increased stimulation, and increased 
anxiety. There were a number of minor to moderate adverse events during 
acupuncture treatment, but it was mostly well tolerated. CBT had no adverse 
events or side effects. It is important to keep in mind that the reported adverse 
events and side effects found in these studies were far less severe than the 
dangers of overdose and respiratory failure inherent in opioid use. Each 
treatment offered additional benefits beyond analgesia and reduced opioid use, 
and although there was some overlap, many were unique to the individual 
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therapies. CBT had a significant impact on patients' level of depression and 
mood, cannabinoids altered appetites, decreased nausea, sedation, sleep 
quality, global health, emotional functioning, social functioning, and diarrhea, 
while acupuncture's was able to decrease some the negative effects of opioid 
use as well as decrease use of antiemetic drugs in cancer patients. The results in 
electroacupuncture and cannabis were less significant and tended to be more 
limited to specific patient scenarios.  
 The available literature highlighted many of the strengths and weaknesses 
of the 3 therapies, and revealed a potential in the combination of therapies to be 
used in the future. With chronic pain altering a number of different aspects in an 
individual’s life, it can be reasoned that a single form of treatment would be less 
than effective. Those who suffer from chronic lower back pain or rheumatoid 
arthritis commonly suffer from an inability to sleep and/or some level of 
depression, which a prescription of opioids will do little to alleviate. However, with 
a combination of cannabinoids to aid in sleep and CBT to improve mood and 
depression, the relief of pain could be augmented, opioid dependence reduced, 
and a more complete and comprehensive treatment be obtained.  
 A key feature of future studies will be to find the best combination of 
therapies and which populations respond best to different therapies. It stands to 
reason that some level of personalization will be required in the development of 
such treatment regiments. Factors that need to be included are: current 
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diagnosis, time and physical constraints, comorbidities, personal beliefs, 
finances, and social dynamics would be needed to be taken into consideration on 
the onset of combination therapies. Additionally, there are a number of other 
alternative therapies that must be reviewed, including but not limited to: non-
steroidal anti-inflammatory drugs, surgery, antidepressants, anticonvulsants, 
muscle relaxants, topical agents, injections, device implantations, massage, and 
physical therapy. 
 Although the literature showed great potential for these treatments, there 
were a number of limitations and unanswered questions that remain. One of the 
greatest limitations was that the majority of the studies had small sample sizes. 
This created a fair amount of variance between studies and low statistical power 
to see the significance or insignificance of trends. Some of the measurements for 
rating pain, depression, drug dosage and type and route, and other factors were 
not constant, making the comparison of data difficult at times. Overall, creating a 
more uniform system to measure these factors would allow for more accurate 
conclusions to be drawn. Additional factors that need further inquisition include 
differences between types of acupuncture therapy and the numerous forms of 
cannabis therapies that were not included. 
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